Phase 2
N=20
The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers
Muscle Damage · Muscle Inflammation
Bottom Line
View on ClinicalTrials.gov: NCT00805870 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Sep 2012
Primary outcome: Primary: Quadriceps Muscle Strength — 151; 160 lbs — p=>0.05
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Lovaza (omega-3-acid ethyl esters) (Drug); Wheat Germ Oil (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Western Michigan University
- Primary completion
- Dec 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Quadriceps Muscle Strength |
151; 160 | >0.05 |
| PRIMARY Muscle Soreness of the Quadriceps Using an Algometer Strain Gauge |
14.62; 16.46 | >0.05 |
| PRIMARY Creatine Kinase Activity Measured in Blood |
110.20; 167.21 | >0.05 |
| PRIMARY Interleukin-6 Measured in Blood |
0.23; 0.21 | >0.05 |
Summary
The purpose of this study is to determine the effects of fish oil supplementation (Lovaza, GlaxoSmithKline) on muscle strength, muscle soreness and inflammation following exercise.
Eligibility Criteria
Inclusion Criteria
- Healthy, free of disease
- Must be able to swallow capsules
- Free of orthopedic or muscular injuries
- Recreationally active
- Prior consumption of fish and corn with no adverse reactions
Exclusion Criteria
- Use of non-steroidal anti-inflammatory drugs (NSAIDS) or topical analgesics during study enrollment
- Pregnant or nursing
- Food allergy to fish or any components of the pills which includes alpha tocopherol, partially hydrogenated vegetable oils including soybean oils and gelatin and glycerol or wheat germ oil
- Competitive athlete or physically active more than 10 hours per week
Data sourced from ClinicalTrials.gov (NCT00805870). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.